Recipharm spends €3.7m on increasing freeze-drying capacity in Italy

The Masate plant specialises in aseptic manufacturing and filling of parenterals and offers lyophilisation capabilities in both vials and ampoules

Recipharm is to invest in lyophilisation equipment at its plant in Masate, Italy

Recipharm is to invest €3.7 million to expand its lyophilisation capacity in Masate, Italy.

The move is a result of increased demand for this service, the firm said.

The Swedish contract development and manufacturing organisation said the investment is also part of its plan to become a leading provider of freeze-drying services.

It follows the ongoing investment at Recipharm in Wasserburg, Germany, where a further €32m is currently being spent to increase capacity.

The Masate plant, located near Milan, specialises in aseptic manufacturing and filling of parenterals. It offers lyophilisation capabilities in both vials and ampoules.

Recipharm will be adding a new lyophiliser for vials, bringing the total number of machines from five to six and increasing the facility’s capacity by approximately 20%.

The new machine will allow the CDMO to support more drug developers with their stability challenges and meet growing demand for its lyophilisation services, particularly in Europe, China and Japan.

Giorgio Bruno: 'We are experiencing greater demand for lyophilisation capabilities from our customers'

Commenting on the investment, General Manager Giorgio Bruno said: 'We are experiencing greater demand for lyophilisation capabilities from our customers, ranging from some of the largest pharmaceutical companies to small and mid-sized firms.

'As we continue to receive more requests from existing customers and new enquiries from drug developers in new territories, we needed to increase our capacity.'

Companies